Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Proposed Sale · 144

Avalo Therapeutics, Inc.

AVTXNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Aug 11, 2026Accepted Aug 11, 2026, 4:22 PM EDTFiling CIK 2047607Accession 0001950047-26-007948
Share

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer
AVALO THERAPEUTICS, INC.
Issuer CIK
0001534120
SEC file number
001-37590
Phone
410-522-8707
Person for whose account securities are to be sold
JENNIFER RILEY
Relationships to issuer
Officer
Street
1500 LIBERTY RIDGE DRIVE
Street (continued)
SUITE 321
City
WAYNE
State / country code
PA
Postal code
19087

Securities proposed for sale

Securities proposed for sale · 1 reported row
SecurityProposed unitsAggregate market valueUnits outstandingApproximate sale dateExchangeBroker / market maker
Common2,65552,012.2553,630,00008/11/2026NASDAQMorgan Stanley Smith Barney LLC Executive Financial Services

Broker / market maker — proposed row 1, entry 1

Name
Morgan Stanley Smith Barney LLC Executive Financial Services
Street
1 New York Plaza
Street (continued)
8th Floor
City
New York
State / country code
NY
Postal code
10004

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
SecurityAcquiredNature of acquisitionAcquired fromAmount acquiredGift transactionPayment dateNature of payment
Common12/10/2025Shares Purchased Through Employee Stock Purchase PlanIssuer2,655N12/10/2025Cash

Prior-sale reporting

Nothing to report for the preceding three months
Y

Notice signature

Notice date
08/11/2026
Signed
/s/ Jennifer Riley

Company context

Current securities

Historical securities (2)

Recent company filings

  1. 144 filingAug 17, 2026
  2. SCHEDULE 13G/A - filed by Caligan Partners LP regarding Avalo Therapeutics, Inc.Aug 14, 2026
  3. SCHEDULE 13G/A - filed by T. Rowe Price Investment Management, Inc. regarding Avalo Therapeutics, Inc.Aug 14, 2026
  4. SCHEDULE 13G/A - filed by Avoro Capital Advisors LLC regarding Avalo Therapeutics, Inc.Aug 14, 2026
  5. SCHEDULE 13G/A - filed by Deep Track Capital, LP regarding Avalo Therapeutics, Inc.Aug 14, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.